About

Fibrodysplasia ossificans progressiva is an ultra-rare genetic condition that progressively turns muscles, tendons, and ligaments into solid bone, severely restricting movement. Garetosmab is an antibody drug designed to block a protein called activin A, which acts as a central signal in this abnormal bone-forming process. By neutralizing this signal, garetosmab may be able to slow or prevent the formation of new, restrictive bone, potentially helping to preserve mobility for patients.